NAVCO Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
NAVCO Pharmaceuticals's earnings have been declining at an average annual rate of -4.6%, while the Biotechs industry saw earnings growing at 10.9% annually. Revenues have been declining at an average rate of 100% per year.
Key information
-4.6%
Earnings growth rate
13.8%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | -100.0% |
Return on equity | -1,356.2% |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How NAVCO Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -3 | 2 | 0 |
31 Dec 23 | 0 | -2 | 2 | 0 |
30 Sep 23 | 0 | -2 | 1 | 0 |
30 Jun 23 | 0 | -4 | 1 | 0 |
30 Sep 22 | 0 | 0 | 0 | 0 |
30 Sep 21 | 0 | -1 | 0 | 0 |
Quality Earnings: F0U is currently unprofitable.
Growing Profit Margin: F0U is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if F0U's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare F0U's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: F0U is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.8%).
Return on Equity
High ROE: F0U has a negative Return on Equity (-1356.21%), as it is currently unprofitable.